---
figid: PMC7082279__tlcr-09-01-111-f1
figtitle: Resistant mechanisms of TKIs in target therapies of NSCLC
organisms:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- NA
pmcid: PMC7082279
filename: tlcr-09-01-111-f1.jpg
figlink: pmc/articles/PMC7082279/figure/f1/
number: F1
caption: Resistant mechanisms of TKIs in target therapies of NSCLC. EGFR/ALK mutations,
  bypass mechanisms such as MET/ERBB2 amplification, NRG1 fusion, IGF1R activation,
  and EGFR translocation-induced Hippo pathway inhibition result in the activation
  of their downstream pathways, such as PI3K/AKT/mTOR and RAS/RAF/ERK/MAPK, which
  directly confer TKI resistance. TKI, tyrosine kinase inhibitor; NSCLC, non-small-cell
  lung cancer; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase;
  NRG1, neuregulin 1; IGF1R, insulin-like growth factor 1 receptor; KRAS, Kirsten
  rat sarcoma; YAP, Yes-associated protein; TAZ, transcriptional coactivator with
  the PDZ-binding motif.
papertitle: Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell
  lung cancer.
reftext: Chennianci Zhu, et al. Transl Lung Cancer Res. 2020 Feb;9(1):111-138.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9704434
figid_alias: PMC7082279__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC7082279__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7082279__tlcr-09-01-111-f1.html
  '@type': Dataset
  description: Resistant mechanisms of TKIs in target therapies of NSCLC. EGFR/ALK
    mutations, bypass mechanisms such as MET/ERBB2 amplification, NRG1 fusion, IGF1R
    activation, and EGFR translocation-induced Hippo pathway inhibition result in
    the activation of their downstream pathways, such as PI3K/AKT/mTOR and RAS/RAF/ERK/MAPK,
    which directly confer TKI resistance. TKI, tyrosine kinase inhibitor; NSCLC, non-small-cell
    lung cancer; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma
    kinase; NRG1, neuregulin 1; IGF1R, insulin-like growth factor 1 receptor; KRAS,
    Kirsten rat sarcoma; YAP, Yes-associated protein; TAZ, transcriptional coactivator
    with the PDZ-binding motif.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Nrg1
  - Erbb2
  - Igfbp4
  - Igfbp1
  - Egfr
  - Sdc4
  - Igf1r
  - Cd74
  - Alk
  - Eml4
  - Tfg
  - Kras
  - ras
  - Hras
  - Rem1
  - Slc7a5
  - Lat2
  - Slc7a8
  - Slc7a6
  - Zhx2
  - Akt1
  - Mdk
  - Yap1
  - NRG1
  - ERBB2
  - IGFBP1
  - IGFBP2
  - IGFBP3
  - IGFBP4
  - IGFBP5
  - IGFBP6
  - IGFBP7
  - EGFR
  - SDC4
  - IGF1R
  - CD74
  - ALK
  - EML4
  - TFG
  - KRAS
  - NRAS
  - HRAS
  - SLC7A5
  - LAT
  - LAT2
  - SLC7A6
  - SLC7A8
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - YAP1
  - del
  - tx
  - mirr
  - fs(1)de1
  - hpo
  - hp
  - Ras64B
  - Ras85D
  - hop
  - bsk
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Stat92E
  - CycE
  - cyc
  - yki
  - NSCLC
---
